Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPN | P05981 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 6/20 | 0.62 |
| ▸ | LMNA | P02545 | 5/20 | 0.62 |
| ▸ | HTT | P42858 | 4/20 | 0.62 |
| ▸ | MEN1 | O00255 | 4/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.62 |
| ▸ | RAB9A | P51151 | 4/20 | 0.60 |
| ▸ | NPC1 | O15118 | 3/20 | 0.60 |
| ▸ | GAA | P10253 | 3/20 | 0.60 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.60 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.60 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.60 |
| ▸ | CCNC | P24863 | 1/20 | 0.55 |
| ▸ | CDK8 | P49336 | 1/20 | 0.55 |
| ▸ | PTPRE | P23469 | 2/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5444273 | 0.87 | HPN (0.76) | HPNMAPTLMNAHTTMEN1 | |
| SCHEMBL2181677 | 0.79 | RAB9A (0.69) | HPNMAPTLMNAHTTMEN1 | |
| SCHEMBL5443077 | 0.78 | HPN (0.64) | HPNMAPTLMNAHTTMEN1 | |
| SCHEMBL5442348 | 0.78 | HPN (0.64) | HPNMAPTLMNAHTTMEN1 | |
| SCHEMBL5435707 | 0.77 | HPN (0.62) | HPNMAPTLMNAHTTMEN1 | |
| SCHEMBL27806626 | 0.77 | LMNA (0.67) | HPNMAPTLMNAHTTMEN1 | |
| SCHEMBL244007 | 0.77 | PTPRE (0.65) | HPNMAPTLMNAHTTMEN1 | |
| SCHEMBL3468827 | 0.75 | PTPRE (0.76) | HPNMAPTLMNAHTTMEN1 | |
| SCHEMBL5441730 | 0.73 | MAPT (0.62) | HPNMAPTLMNAHTTMEN1 | |
| SCHEMBL5448580 | 0.73 | HTT (0.72) | HPNMAPTLMNAHTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017162659-A1 | INTRACELLULAR HEPSIN AS THERAPEUTIC TARGET FOR THE TREATMENT OF CANCER WITH CENTROSOME AMPLIFICATION | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-28 | — | — | WO | disclosed |
| US-9182402-B2 | Hepsin inhibitors | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2015-11-10 | — | — | US | disclosed |
| US-20140127127-A1 | HEPSIN INHIBITORS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2014-05-08 | — | — | US | disclosed |
| US-8664266-B2 | Hepsin inhibitors | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2014-03-04 | — | — | US | disclosed |
| US-8664266-B2 | Hepsin inhibitors | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2014-03-04 | — | — | US | disclosed |
| US-20130289105-A1 | HEPSIN INHIBITORS | FRED HUTCHINSON CANCER CENTER | 2013-10-31 | — | — | US | disclosed |
| US-20130289105-A1 | HEPSIN INHIBITORS | FRED HUTCHINSON CANCER CENTER | 2013-10-31 | — | — | US | disclosed |
| US-8450334-B2 | Hepsin inhibitors | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450334-B2 | Hepsin inhibitors | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2013-05-28 | — | — | US | disclosed |
| US-20110144139-A1 | HEPSIN INHIBITORS | FRED HUTCHINSON CANCER RESEARCH CENTER | 2011-06-16 | — | — | US | disclosed |
| US-20110144139-A1 | HEPSIN INHIBITORS | FRED HUTCHINSON CANCER RESEARCH CENTER | 2011-06-16 | — | — | US | disclosed |
| WO-2009151920-A2 | HEPSIN INHIBITORS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140127127-A1 | HEPSIN INHIBITORS | HPN, TMPRSS2, SPINT2 | HPN 1/4885MAPT 3363/4885LMNA 2281/4885 |
| US-20110144139-A1 | HEPSIN INHIBITORS | HPN, TMPRSS2, SPINT2 | HPN 1/4885MAPT 3363/4885LMNA 2281/4885 |
| US-20130289105-A1 | HEPSIN INHIBITORS | HPN, TMPRSS2, SPINT2 | HPN 1/4885MAPT 3363/4885LMNA 2281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.